Merck KGaA (ETR:MRK) reported accelerating organic sales and earnings growth in the second quarter of 2026, led by Life Science and Electronics, and raised its full-year outlook for sales, EBITDA pre and earnings per share. Organic sales grew 4.1%, while currency effects reduced sales by 1.1% and portfolio effects added 0.4%. Life Science EBITDA pre rose to €700 million, and the margin increased 50 basis points to 29%. Healthcare Sales Reflect Portfolio Effects and U.S. CompetitionHealthcare reported sales rose 2.4% to €2.2 billion, but organic sales declined 3.4%. Healthcare organic sales are expected to decline 4% to 2%, with Merck assuming zero U.S. Mavenclad sales from August.